TY - JOUR
T1 - The measurement of a fibrinogen α C-chain 5.9kDa fragment (FIC 5.9) using MALDI-TOF MS and a stable isotope-labeled peptide standard dilution
AU - Sogawa, Kazuyuki
AU - Kodera, Yoshio
AU - Noda, Kenta
AU - Ishizuka, Yusuke
AU - Yamada, Mako
AU - Umemura, Hiroshi
AU - Maruyama, Katsuya
AU - Tomonaga, Takeshi
AU - Yokosuka, Osamu
AU - Nomura, Fumio
N1 - Funding Information:
This work was supported in part by a grant from the Japanese Ministry of Education, Culture, Sports, Science, and Technology .
PY - 2011/5/12
Y1 - 2011/5/12
N2 - Background: We previously identified a 5.9. kDa peptide fragment of fibrinogen α C-chain (FIC 5.9) as a novel biomarker candidate for heavy drinking. In an effort to improve FIC 5.9 measurement for potential use in clinical diagnostics, we combined the ClinProt System and a stable isotope-labeled peptide standard dilution as a simple and reproducible system for measuring FIC 5.9. Methods: We analyzed 104 serum samples that were obtained from patients with alcohol dependency, from patients with chronic hepatitis C, and from healthy volunteers. Serum FIC 5.9 levels were measured using the ClinProt system with and without a stable isotope-labeled synthetic FIC 5.9 as an internal standard. Results: The within-day and between-day CVs were significantly smaller with stable isotope dilution mass spectrometry (SID-MS) than with conventional MALDI-TOF MS. Of the two different MALDI-TOF MS platforms, we obtained concordant results with SID-MS. Furthermore, only SID-MS detected a small but significant difference between the serum FIC 5.9 levels in the chronic hepatitis C group and the controls. Conclusions: MALDI-TOF MS with a stable isotope-labeled peptide spike can determine serum FIC 5.9 levels more precisely than conventional MS. This will make inter-laboratory FIC 5.9 comparisons possible.
AB - Background: We previously identified a 5.9. kDa peptide fragment of fibrinogen α C-chain (FIC 5.9) as a novel biomarker candidate for heavy drinking. In an effort to improve FIC 5.9 measurement for potential use in clinical diagnostics, we combined the ClinProt System and a stable isotope-labeled peptide standard dilution as a simple and reproducible system for measuring FIC 5.9. Methods: We analyzed 104 serum samples that were obtained from patients with alcohol dependency, from patients with chronic hepatitis C, and from healthy volunteers. Serum FIC 5.9 levels were measured using the ClinProt system with and without a stable isotope-labeled synthetic FIC 5.9 as an internal standard. Results: The within-day and between-day CVs were significantly smaller with stable isotope dilution mass spectrometry (SID-MS) than with conventional MALDI-TOF MS. Of the two different MALDI-TOF MS platforms, we obtained concordant results with SID-MS. Furthermore, only SID-MS detected a small but significant difference between the serum FIC 5.9 levels in the chronic hepatitis C group and the controls. Conclusions: MALDI-TOF MS with a stable isotope-labeled peptide spike can determine serum FIC 5.9 levels more precisely than conventional MS. This will make inter-laboratory FIC 5.9 comparisons possible.
KW - Alcoholism
KW - FIC 5.9
KW - MALDI-TOF MS
KW - Serum
KW - Stable isotope-labeled
UR - http://www.scopus.com/inward/record.url?scp=79954992342&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79954992342&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2011.02.029
DO - 10.1016/j.cca.2011.02.029
M3 - Article
C2 - 21354123
AN - SCOPUS:79954992342
SN - 0009-8981
VL - 412
SP - 1094
EP - 1099
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
IS - 11-12
ER -